Buscar
Nuvation Bio Inc
NUVBAñadir a la lista de seguimiento
6.330USD
-0.360-5.37%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
2.20BCap. mercado
PérdidaP/E TTM
Más Datos de Nuvation Bio Inc Compañía
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Información de Nuvation Bio Inc
Símbolo de cotizaciónNUVB
Nombre de la empresaNuvation Bio Inc
Fecha de salida a bolsaJul 01, 2020
Director ejecutivoHung (David T)
Número de empleados220
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 01
Dirección1500 Broadway
CiudadNEW YORK
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal10036
Teléfono13322086102
Sitio Webhttps://www.nuvationbio.com/
Símbolo de cotizaciónNUVB
Fecha de salida a bolsaJul 01, 2020
Director ejecutivoHung (David T)
Ejecutivos de Nuvation Bio Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
59.28M
-1.69%
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
200.00K
+50.00%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+64.10%
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
61.37K
--
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
12.67K
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
10.00K
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Lead Independent Director
Lead Independent Director
5.00K
--
Dr. Gary Hattersley, Ph.D.
Dr. Gary Hattersley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
59.28M
-1.69%
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
200.00K
+50.00%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+64.10%
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
61.37K
--
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Nuvation Bio Inc?
Los cinco principales accionistas de Nuvation Bio Inc son: Dr. David T. Hung, M.D.
¿Cuántas instituciones poseen acciones de Nuvation Bio Inc (NUVB)?
A fecha de 2026Q1, 421 instituciones poseen acciones de Nuvation Bio Inc, con un valor de mercado combinado de aproximadamente 228.36M, lo que representa el 65.58% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -32847901.00.